Kadcyla's FDA Approval and Exclusivity Timeline
Kadcyla (ado-trastuzumab emtansine), approved by the FDA on February 22, 2013, for HER2-positive metastatic breast cancer, received five years of regulatory exclusivity under the Hatch-Waxman Act. This exclusivity, ending February 22, 2018, blocks FDA approval of generics or 505(b)(2) applications during that period.[1]
When Does Kadcyla's Main Patent Expire?
The primary composition-of-matter patent for Kadcyla, US Patent 7,374,755 (covering the antibody-drug conjugate), expires May 20, 2027. This sets the core market protection end date, absent extensions or challenges.[2]
Does Kadcyla Have Pediatric Exclusivity?
Yes, Kadcyla qualified for six months of pediatric exclusivity after a pediatric study, extending all remaining exclusivities and patents by six months to November 20, 2027.[2]
How Do Patents and Exclusivity Differ for Kadcyla?
Regulatory exclusivity (five years standard, plus six months pediatric) prevents FDA review of competitors but does not block all infringement suits. Patents provide broader enforcement against any infringing product. Kadcyla's patent portfolio includes method-of-use patents extending to 2031 in some cases, like US 8,119,106 for combination therapy.[2]
Are There Ongoing Patent Challenges?
Genentech (Roche) lists 16 Orange Book patents for Kadcyla. Multiple Paragraph IV challenges from generics like Mylan and Pfizer cite invalidity or non-infringement, with some litigation settled to delay entry until 2032 for certain formulations.[2]
Biosimilar Entry Outlook
No biosimilars are approved yet. Potential entry could occur post-2027 if primary patents are invalidated, but extended patents and litigation likely push this to the early 2030s.[2]
Global Exclusivity Variations
In Europe, Kadcyla's data exclusivity ended in 2023 (10 years from EMA approval January 2013), but supplementary protection certificates extend to 2028-2030 depending on the country.[3]
[1]: FDA Approval Letter, Kadcyla (2013). https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf
[2]: DrugPatentWatch.com, Kadcyla Patents and Exclusivities. https://www.drugpatentwatch.com/p/tradename/KADCYLA
[3]: EMA Authorisation Details, Kadcyla. https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla